TECENTRIQ

Connecting patients to an important advancement in the management of lung cancer

With 6 indications across small- and non-small-cell lung cancer, TECENTRIQ is committed to advancing the standard of care in an area of high unmet need.1
 

TECENTRIQ—alone or in combination with cytotoxic therapy—has improved patient outcomes in metastatic non-small-cell lung cancer (NSCLC). It was also the first treatment advance in small-cell lung cancer (SCLC) in over 20 years, showing a significant survival benefit in a hard-to-treat patient population.2-6

Now, with adjuvant TECENTRIQ, the goal is cure

TECENTRIQ is the first and only approved adjuvant immunotherapy in PD-L1-high (≥50%) resected stage II-III* NSCLC, excluding EGFR/ALK+ disease. Learn how you can further reduce the risk of recurrence with adjuvant TECENTRIQ.1,7

ALK, anaplastic large-cell lymphoma kinase; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1, TNM, The Tumour/Nodal Involvement/Metastatic Spread Classification of Malignant Tumours.

*Stage II-IIIA (TNM 7th edition)/select stage II-IIIB (TNM 8th edition).1,8

LUNG INDICATIONS

See how TECENTRIQ can help patients with NSCLC and SCLC.

Blue lungs icon
Green lungs icon

Evidence-based treatment based on an extensive clinical trial programme addressing the unmet needs in patients with NSCLC and SCLC 

 

TECENTRIQ indications1,8

 

Early-stage NSCLC

 

TECENTRIQ as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC.

 

The staging edition agnostic "high risk of recurrence" definition refers to patients with stage II-IIIA per the 7th edition of the TNM staging system (select stage II-IIIB based on the 8th edition).

 

Metastatic NSCLC

 

TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

 

TECENTRIQ, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

 

TECENTRIQ as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥50% TC or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.

 

TECENTRIQ as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK+ NSCLC should also have received targeted therapy before receiving TECENTRIQ.

 

SCLC

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES-SCLC).

 

What this means for patients with lung cancer

  • Dr. John Conibear speaks about what recent advancements in immunotherapy mean for patient care.

    The future of small cell lung cancer care.

     

    What makes SCLC different from other types of lung cancer?

    Small cell lung cancer is the least common form of lung cancer that we treat. It makes up approximately 15% of lung cancer. Patients who present with small cell lung cancer tend to have large primary tumours and large lymph nodes within their chest.

    As a consequence of those large volume tumours and lymph nodes, they suffer with cough and breathlessness and often chest pain.
    The survival from small cell lung cancer is unfortunately much worse than non-small cell lung cancer even with standard of care treatment they only survive 10 months. As a consequence, there’s very few patients who live to 5 years.

     

    What are some of the challenges in treating these patients?

    The challenge that I face when I treat patients with small cell lung cancer is that the cancer itself grows quickly. The majority of patients that I treat have advanced incurable disease. As a consequence of that, I typically use combination chemotherapy. When I first meet patients with extensive-stage small cell lung cancer, I explain to them that their disease is likely to respond well to chemotherapy. In fact, many of those patients are impressed when they see the response they’ve had to their platinum doublet chemotherapy. Unfortunately though, many of them are devastated when they come back only after a short period of time later to find their disease has regrown and on receiving further treatment does not respond as well as it did.

    For over 20 years, combination chemotherapy has been the standard of care. Despite over 40 clinical trials, there hasn’t yet been any significant change to that standard of care.

     

    Tell us about what recent advancements in immunotherapy mean for patient care

    When you combine chemotherapy with immunotherapy you’re combining a treatment which can gain control of the disease quickly. The immunotherapy is then allowed time to mount an immune response which offers the patient durability. It’s now recognised that tumours with high mutational burden are the ones that respond best to immunotherapy drug treatment. Small cell lung cancer is just one of those tumours. As a consequence of that, when patients with small cell lung cancer receive immunotherapy, the immunotherapy encourages their immune system to attack their tumour cells.

     

    What are you most excited about when you look at how the treatment landscape is evolving for patients with SCLC?
    Over the past 10 years, there have been dramatic developments in the management of patients with lung cancer.

     

    Through advances in our understanding of lung cancer, we’ve seen new drugs such as immunotherapy, new types of chemotherapy, new targeted therapy but also advances in radiation delivery and even surgery.

     

    What do you anticipate for the future in SCLC?
    Patients with extensive-stage small cell have disease which grows quickly. You therefore need treatment which can gain control of the disease quickly, as with most new treatments that we see in oncology, we examine their benefits in the advanced setting.
    I’m hopeful that in future, those benefits will be examined in the limited stage setting of small cell lung cancer. Now, patients who I treat with lung cancer have a wealth of new treatment options, and it’s important that we personalise those treatment options to their disease. 

    View video transcript

Dr. John Conibear speaks about what recent advancements in immunotherapy mean for patient care.

  • Listen to Tommy, a lung cancer survivor who now uses his voice to raise awareness of the disease.

    I am very happy to be an advocate these days because so many good things have started to happen in the last three, four, five years. The numbers of survivors are increasing all the time, so it is very good to be able to say that. The same diagnosis for different people does mean different things. We realise when you talk to another cancer patient that we have something in common that we share, that nobody else can share. I’m not a doctor but I can tell you about the opportunities there are, there are a lot of new opportunities and I can compare to when I was diagnosed myself 15 years ago. There is next generation sequencing, there are targeted therapies, there are immunotherapies, there are a lot of options so you can live longer with your cancer.

     

    Continued trials are essential to help advance patient care. Lung Cancer Europe has for the last three years investigated how the lack of cancer care is in the European Union. We will help all the global lung cancer coalitions, we have enquiries all over the world where people think about lung cancer. If we are looking at the future, [there will be] even more medicines, more targeted therapies, and I think it is essential that if we’re going to fight lung cancer and beat it we have to have trials.

    View video transcript

Listen to Tommy, a lung cancer survivor who now uses his voice to raise awareness of the disease.

Resources

Explore more

Download therapy administration overview and dosing options

Curious to see more resources and download material?

Published references and articles about TECENTRIQ.
Connecting YOU WITH YOUR PATIENTS
doctor_patient.jpg

CONNECTING YOU WITH YOUR PATIENTS

At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC). 

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.

Connecting TECENTRIQ and COMBINATIONS
A female research scientist wearing glasses.

CONNECTING TECENTRIQ AND COMBINATIONS

TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to explore new combinations for better patient outcomes (ref. SmPC).

In many difficult-to-treat tumour types with a high unmet need, including metastatic urothelial carcinoma, triple negative breast cancer and lung cancer (non-small cell lung cancer and small cell lung cancer), TECENTRIQ has shown significant improvements in progression-free and/or overall survival (ref. SmPC). Importantly, treatment can be tailored (i.e., in combination with the standard of care, or different dosing schedules) according to the type of cancer and the patient’s individual needs (ref. SmPC).
Read SmPC for more details

The multiple indications of TECENTRIQ (ref. SmPC)
provide a wealth of data to inform treatment decision-making and deliver valuable reassurance when considering the needs of your patients with cancer. Please see the specific indications for more information.

Connecting PATIENTS TO THEIR LOVED ONES
patients_sisters.jpg

CONNECTING PATIENTS TO THEIR LOVED ONES

TECENTRIQ treatment offers the potential to improve treatment outcomes and maintain patient quality of life in your difficult to treat cancer patients, so they can hopefully spend more time with their loved ones.

TECENTRIQ is approved in metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer and triple negative breast cancer (ref. SmPC).

  • References & Notes

    References & Notes

    1. TECENTRIQ (atezolizumab), Summary of Product Characteristics. June 2022. Available from: https://www.ema.europa.eu/ (Accessed June 2022).
    2. Rittmeyer A, Barlesi F, Waterkampet D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
    3. Socinski MA, Jotte RM, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.
      N Engl J Med. 2018;378:2288-2301.
    4. West H, Batus M, Bernickeret E, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
      Lancet Oncol. 2019;20:924-937.
    5. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328-1339.
    6. Horn L, Mansfield AS, Szczęsna A, et al. IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.
      N Engl J Med. 2018;379:2220-2229.
    7. Felip E, Altorki N, Zhou C, et al; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
    8. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11:39-51.